Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
LifeCycle Pharma A/S |
---|---|
Information provided by: | LifeCycle Pharma A/S |
ClinicalTrials.gov Identifier: | NCT00608894 |
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine, each in combination with prednisone, for the treatment of autoimmune hepatitis (AIH).
Condition | Intervention | Phase |
---|---|---|
Autoimmune Hepatitis |
Drug: LCP-Tacro + prednisone Drug: Azathioprine + prednisone |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase II, Open-Label, Multi-Center, Prospective, Randomized Study of LCP-Tacro Tablets vs. Azathioprine, in Combination With Corticosteroids, for the Treatment of Autoimmune Hepatitis |
Estimated Enrollment: | 60 |
Study Start Date: | December 2007 |
Estimated Study Completion Date: | March 2009 |
Estimated Primary Completion Date: | March 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
LCP-Tacro + prednisone
|
Drug: LCP-Tacro + prednisone
LCP-Tacro tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
|
2: Active Comparator
Azathioprine + prednisone
|
Drug: Azathioprine + prednisone
Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
|
An open-label, multi-center, prospective, randomized study to evaluate the efficacy, safety and tolerability of LCP-Tacro tablets given once daily vs. azathioprine for the treatment of autoimmune hepatitis (AIH).
Patients with histologically confirmed chronic hepatitis who fulfill criteria established by the International Autoimmune Hepatitis Group (IAIHG) and Inclusion and Exclusion criteria will be enrolled after having signed an informed consent document.
Up to 60 patients will be randomized (1:1) to receive treatment with LCP-Tacro + prednisone vs. azathioprine (AZA) + prednisone.
Patients will also commence treatment with prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Mayo Clinic - Phoenix | |
Phoenix, Arizona, United States, 85054 | |
United States, Florida | |
Mayo Clinic - Jacksonville | |
Jacksonville, Florida, United States, 32216 | |
United States, Illinois | |
Northwestern University | |
Chicago, Illinois, United States, 60611 | |
United States, Minnesota | |
Mayo Clinic | |
Rochester, Minnesota, United States, 55905 | |
University of Minnesota | |
Minneapolis, Minnesota, United States, 55455 | |
United States, New York | |
Mount Sinai Medical Center | |
New York, New York, United States, 10029 | |
United States, Texas | |
St. Luke's Advanced Liver Therapies | |
Houston, Texas, United States, 77030 | |
United States, Virginia | |
Virginia Commonwealth University | |
Richmond, Virginia, United States, 23298 | |
Canada, Alberta | |
Zeildler Ledcor Centre | |
Edmonton, Alberta, Canada, T6G 2X8 | |
Heritage Medical Research Clinic | |
Calgary, Alberta, Canada, T2N 4N1 | |
Canada, Manitoba | |
John Buhler Research Centre, University of Manitoba Health Sciences Centre | |
Winnipeg, Manitoba, Canada, R3E 3P4 | |
Canada, Nova Scotia | |
Queen Elizabeth II Health Sciences Centre | |
Halifax, Nova Scotia, Canada, B3H 2Y9 |
Principal Investigator: | Gerald Y Minuk, M.D. | University of Manitoba Health Sciences Centre, Winnipeg |
Principal Investigator: | Andrew Mason, MD | University of Alberta, Edmonton |
Principal Investigator: | Russell H Wiesner, MD | Mayo Clinic - Rochester, MN |
Principal Investigator: | John M Vierling, MD | Baylor College of Medicine |
Principal Investigator: | Velimir A Luketic, MD | Virginia Commonwealth University, Richmond, VA |
Principal Investigator: | Joseph A Odin, MD, PhD | Mount Sinai Medical Center, New York, NY |
Principal Investigator: | Elizabeth Carey, MD | Mayo Clinic - Phoenix |
Principal Investigator: | John R Lake, MD | University of Minnesota |
Principal Investigator: | Barry G Rosser, MD | Mayo Clinic |
Principal Investigator: | Steven L Flamm, MD | Northwestern University |
Principal Investigator: | Kevork M Peltekian, MD | Queen Elizabeth II Health Sciences Centre |
Principal Investigator: | Mark G Swain, MD | University of Calgary |
Responsible Party: | LifeCycle Pharma A/S ( Lawrence Chodoff, Pharm.D. ) |
Study ID Numbers: | LCP-Tacro Study 2016, Not applicable. |
Study First Received: | January 23, 2008 |
Last Updated: | June 23, 2008 |
ClinicalTrials.gov Identifier: | NCT00608894 |
Health Authority: | United States: Food and Drug Administration; Canada: Health Canada |
Autoimmune hepatitis Chronic active hepatitis |
Hepatitis Prednisone Liver Diseases Azathioprine Autoimmune Diseases Digestive System Diseases |
Hepatitis, Chronic Benzocaine Tacrolimus Autoimmune hepatitis Hepatitis, Autoimmune |
Anti-Inflammatory Agents Antimetabolites Antimetabolites, Antineoplastic Antineoplastic Agents, Hormonal Immune System Diseases Molecular Mechanisms of Pharmacological Action Immunologic Factors Antineoplastic Agents |
Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Immunosuppressive Agents Glucocorticoids Hormones Pharmacologic Actions Therapeutic Uses Antirheumatic Agents |